BGB-11417

Phase 2Small molecule

BeiGene

BGB-11417 is one of 112 small molecule programs targeting Mantle Cell Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mantle Cell LymphomaActive, not recruiting

Acute Myeloid LeukemiaRecruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Mature B-Cell MalignanciesActive, not recruiting

Mantle Cell LymphomaPhase 1/Phase 2

Active, not recruiting

Acute Myeloid LeukemiaPreclinical

Recruiting

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

Mature B-Cell MalignanciesPhase 1

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Phase 3

32 2

Fludara

Sanofi

Phase 3

15 3

Vanflyta

Daiichi Sankyo

Phase 3

13 4

Peony

Takeda

Phase 3

6 5

Retin-a

VValeant Pharmaceuticals

Phase 3

2 6

Bicnu

MMelissa K Accordino

Phase 3

1 7

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 8

Active Comparator

Moderna

Phase 3

1 9

Experimental

Biogen

Phase 3

1 10

Valspodar

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Mature B-Cell Malignancies

NCT04883957

Q1 2027

Phase 1/2Active, not recruiting

Mantle Cell Lymphoma

NCT05471843

Q3 2027

Phase 2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT05479994

Q1 2028

PreclinicalRecruiting

Acute Myeloid Leukemia

NCT04771130

Clinical

Trials by Indication[1]

TED1 trial

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06463691·30 enrolled

Mantle Cell Lymphoma1 trial

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting· BeiGene logo

BeiGene·Phase 1/2·NCT05471843·125 enrolled

Chronic Lymphocytic Leukemia1 trial

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting· BeiGene logo

BeiGene·Phase 2·NCT05479994·100 enrolled

Acute Myeloid Leukemia1 trial

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

Recruiting· BeiGene logo

BeiGene·Preclinical·NCT04771130·260 enrolled

Mature B-cell Malignancies1 trial

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies

Active, not recruiting· BeiGene logo

BeiGene·Phase 1·NCT04883957·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for BGB-11417. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGB-11417 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGB-11417. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeiGene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BeiGene

BGB-11417

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q3 2027

Q1 2028

Trials by Indication[1]

TED1 trial

Mantle Cell Lymphoma1 trial

Chronic Lymphocytic Leukemia1 trial

Acute Myeloid Leukemia1 trial

Mature B-cell Malignancies1 trial

References

Drug Info

Quick Facts

Related News